ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Editorial: Hypertrophic Cardiomyopathy and Precision Medicine in Cardiovascular Disease.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular targets in diseased cells and tissues are the basis for precision medicine that stratifies patients into specific subgroups to develop targeted therapies. Myosin heavy chain (MHC) gene isoforms encode the proteins that form the thick filaments in muscle that enable muscle contraction. Management of familial hypertrophic cardiomyopathy has relied on surgical and symptomatic medical (pharmacological) treatment. However, in April 2022, the US Food and Drug Administration (FDA) approved a small molecule that selectively but reversibly inhibits sarcomeric myosin, mavacamten (MYK-461, Camzyos) for adults with symptomatic hypertrophic cardiomyopathy, New York Heart Association (NYHA) class II-III. Mavacamten is a first-in-class, precision medicine for patients with symptomatic hypertrophic obstructive cardiomyopathy that inhibits cardiac myosin and reduces actin-myosin interactions to reduce left ventricular outflow tract obstruction, improve exercise capacity, and reduce symptoms. This editorial aims to introduce how understanding the genetic and molecular basis of hypertrophic cardiomyopathy has resulted in a novel approach to precision medicine in cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.